Abstract

Background: Asthma is the most common chronic disease of childhood and a major source of childhood health burden worldwide. These burdens are particularly marked when children experience characteristic ‘symptom flare-ups’ or acute asthma exacerbations (AAEs). AAEs are associated with significant health and economic impacts, including acute Emergency Department visits, occasional hospitalizations, and rarely, death. To treat children with AAEs, several medications have been studied and used.

Methods: We conducted a narrative review of the literature with the primary objective of understanding the evidence of their efficacy. We present this efficacy evidence in the context of a general stepwise management pathway for paediatric AAEs. This framework is developed from the combined recommendations of eight established (inter)national paediatric guidelines.

Discussion: Management of paediatric AAE centres around four major care goals: (1) immediate and objective assessment of AAE severity; (2) prompt and effective medical interventions to decrease respiratory distress and improve oxygenation; (3) appropriate disposition of patient; and (4) safe discharge plans. Several medications are currently recommended with varying efficacies, including heliox, systemic corticosteroids, first-line bronchodilators (salbutamol/albuterol), adjunctive bronchodilators (ipratropium bromide, magnesium sulfate) and second-line bronchodilators (aminophylline, i.v. salbutamol, i.v. terbutaline, epinephrine, ketamine). Care of children with AAEs is further enhanced using clinical severity scoring, pathway-driven care and after-event discharge planning.

Conclusions: AAEs in children are primarily managed by medications supported by a growing body of literature. Continued efforts to study the efficacy of second-line bronchodilators, integrate AAE management with long-term asthma control and provide fair/equitable care are required.

Keywords: algorithms, asthma, bronchodilator agents, glucocorticoids, paediatric emergency medicine, paediatrics.

Citation

Leung JS. Paediatrics: how to manage acute asthma exacerbations. Drugs in Context 2021; 10: 2020-12-7.
DOI: 10.7573/dic.2020-12-7

Introduction

Asthma is the most common chronic disease affecting children worldwide. According to international consensus, asthma is defined as a chronic inflammatory disorder associated with variable airflow obstruction and bronchial hyperresponsiveness. Globally, ~11–14% of all children report asthma symptoms, with increasing prevalence reported worldwide.

Measured by school absences, Emergency Department (ED) visits, hospitalization, and parental work absence, paediatric asthma is a major burden on childhood and family health worldwide. Poorly controlled childhood asthma is associated with a lower quality of life, lower cardiovascular fitness, increased missed school days in children and decreased caregiver productivity. The resulting economic costs are substantial, including 10 million school days lost, $726.1 million lost from parental work absence in the United States and $120–140 million in direct patient care costs in Canada. These human and economic impacts are critically apparent when children experience acute asthma exacerbations (AAEs). AAEs or ‘flare-ups’ are defined as acute or subacute episodes of progressive increases in asthma symptoms associated with airflow obstruction. AAES are associated with high morbidity and, on rare occasions, mortality, particularly with children from visible minorities and living in socioeconomically disadvantaged environments. As such, AAEs are one of the most common reasons children seek ED care worldwide. In the United States, 3 million asthma exacerbations in children <18 years of age were reported in 2017, leading to 626,923 ED visits and 75,905 admissions (a top-three cause). In Canada,
2015 and 2016, 3–10% of all ED visits by children were due to asthma exacerbations, leading to ~6000 hospitalizations and ~8 ED visits for every hospitalization.5,10

Timely and appropriate management of an AAE is lifesaving. Multiple medications have been recommended based on varying degrees of evidence of their efficacy, creating some confusion. As such, we felt it was necessary to provide an evidence-based review of the medications used to manage paediatric AAEs. The primary objective of this review is to understand the effectiveness of medications used to manage children presenting with AAEs. Our secondary objective is to contextualize how these drugs are utilized by healthcare providers. We compare and contrast medication recommendations and discuss general care principles described in several national and international paediatric guidelines on AAE management. These descriptions are embedded within a stepwise approach to acute AAE paediatric management synthesized from the included guidelines.

Methods

This review focuses on acute pharmacotherapy for the treatment of paediatric AAE. Baseline asthma control strategies (including allergen avoidance and therapies, harm reduction, and smoking cessation) were determined to be beyond the scope of this review according to the a priori determined objectives described earlier. The author recognizes the significant negative impact of economic, ethnic and social inequality on children with asthma.5,8 However, an in-depth discussion on this important topic is also beyond the scope of this review. Finally, mechanical ventilation strategies were deemed beyond the review’s scope.

To identify relevant articles, the author conducted a search literature using OVID Medline between 1946 and December 1, 2020, including articles (Epub Ahead of Print, Abstracts, English, Humans, In-process and other nonindexed citations) with the following MESH terms: ‘asthma’ (with subheadings drug therapy (/dh), epidemiology (/ep), physiology (/ph), statistics & numerical data (/sn), therapy (/th)) AND ‘pediatrics’, revealing 460 articles. When multiple studies were found on a topic, the author prioritized systematic review and meta-analysis data when available. A search of the Cochrane Review Library was completed with the search terms ‘asthma’ (all dates, status, language, type but limited to child health topics), revealing 204 articles. All results were manually reviewed for inclusion and appropriate information abstracted. With review articles, references were assessed and primary evidence sought. Epidemiological data were pulled from United States and Canadian government sources. Finally, the author reviewed the most current AAE management guidelines from the eight most prominent (inter)national organizations6,7,11–16 (Table 1). These guidelines were selected as they were publicly available, free of major financial influence, and developed by reputed experts with clearly reported methodologies and references.

### Table 1. International and national-level guidelines for paediatric acute asthma exacerbations included in this review6,7,11–16

| Guideline abbreviation (Reference Number) | Most recent publication year | Country of origin | English language | Industry sponsored | Clear methods and expert involved | Clear presentation | Clear references |
|------------------------------------------|-----------------------------|------------------|------------------|-------------------|---------------------------------|------------------|-----------------|
| GINA (7)                                 | 2020                        | International    | Y                | N                 | Y                               | Y                | Y               |
| ICON (6)                                 | 2012                        | International    | Y                | N                 | Y                               | Y                | Y               |
| NHLBI (11)                               | 2007                        | United States    | Y                | N                 | Y                               | Y                | Y               |
| PRACTALL (12)                            | 2007                        | Europe and North America | Y            | Y                 | Y                               | Y                | Y               |
| National Asthma Council (13)             | 2019                        | Australia        | Y                | N                 | Y                               | Y                | Y               |
| BTS/SIGN (14)                            | 2016                        | United Kingdom   | Y                | N                 | Y                               | Y                | Y               |
| CPS (15)                                 | 2012                        | Canada           | Y                | N                 | Y                               | Y                | Y               |
| TREKK (16)                               | 2020                        | Canada           | Y                | N                 | Y                               | Y                | Y               |

BTS/SIGN, British Thoracic Society/Scottish Intercollegiate Guidelines Network; CPS, the Canadian Paediatric Society; GINA, the Global Initiative for Asthma; ICON, International Consensus on Pediatric Asthma; NHLBI, National Heart, Lung, and Blood Institute Expert Panel 3; PRACTALL, joint guidelines from the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology; TREKK, Translating Emergency Knowledge for Kids.
In lieu of standard reporting guidelines for narrative reviews, this article aims to fulfil criteria from the SANRA scale for assessing narrative review quality.17

**Results**

Overall goals of care

The goals of care for managing children with AAEs are generally understood and shared across multiple guidelines.15 These goals are the basis of a stepwise approach to managing paediatric AAEs and are (1) immediate and objective assessment of AAE severity; (2) prompt and effective medical interventions to decrease respiratory distress and improve oxygenation; (3) appropriate disposition of patient and (4) a safe discharge home plan. The majority of this review is organized around this stepwise approach.

Immediate and objective assessment of asthma exacerbation severity

A focused history and physical examination are recommended to (1) confirm the diagnosis of an AAE, (2) determine aetiology, (3) determine AAE severity and (4) estimate the risk factors for intensive care unit (ICU) admission.15 In order to provide appropriate and effective treatment, it is crucial to promptly determine the severity of the AAE. Children with a critical AAE should not have their treatment delayed.

Pertinent clinical information includes previous asthma history, exposure to triggers and asthma medications administered (adherence, dose, timing of medications, social barriers to care). Of critical importance are questions on risk factors for fatal asthma (Table 2). Children with these risk factors require caution and specialist involvement with their care.

By far, respiratory viral infections are the most common trigger for AAEs in children, accounting for ~85% of cases.18,19 The most common identified virus is human rhinovirus (74%), whereas respiratory syncytial virus and influenza can also trigger severe AAEs. Additional triggers include allergens, drugs (i.e. nicotine smoking), exercise and environmental irritants.20 Of note, long-term asthma control significantly reduces the likelihood that exposure to the previously mentioned triggers results in an AAE and that medications fail to treat an AAE.7 Pathophysiologically, AAEs evolve from a complex interplay of three processes, namely airway inflammation, bronchiolar hyper-responsiveness and bronchial constriction20–23 (Figure 1).

Children with poorly controlled baseline asthma have structural remodelling, such as hypertrophic smooth muscle, thickened basement membranes and collagen deposition, resulting in decreased compliance.23,24 Pharmacological management of AAEs is the mainstay of therapy and targets multiple steps of the previous pathophysiology. However, the previous medications do not address permanent changes from poorly controlled asthma.

In contrast to adults, supplemental pulmonary function tests (PFTs) measuring peak expiratory flow (PEF) and/or forced expiratory volume (FEV1) are de-emphasized in young children. Most children <5 years of age are not developmentally capable of performing these tests appropriately. In a prospective single-centre cohort study, only 54% of children performed initial bedside PEF measures and 48% of tests led to valid information at the start and end of treatment. Children that completed PEF were older (mean 11.2 ± 3.2 years).25 Likewise, chest x-rays are

| Table 2. Risk factors for dying from acute asthma exacerbations.11,98 |
|--------------------------------------------------|
| **Asthma history:**                                 |
| − Previous severe exacerbation (intubation or intensive care unit admission) |
| − >2 hospitalization for asthma in the past year   |
| − >3 emergency department visits for asthma in the past year |
| − >2 canisters of SABAs/month                      |
| − Difficulty perceiving AAE symptoms or severity of AAE |
| − Lack of written asthma action plan              |
| − Currently using or recently stopped oral corticosteroids (a severe AAE marker) |
| **Social history:**                                |
| − Low socioeconomic status or inner-city residence |
| − Illicit drug use                                 |
| − Major psychosocial problems                      |
| **Comorbidities:**                                 |
| − Cardiovascular disease                           |
| − Another chronic lung disease                     |
| − Chronic psychiatric disease                      |
| − Food allergy                                     |
| **AAE, acute asthma exacerbation; SABA, short-acting β-agonist.** |
REVIEW – How to manage paediatric acute asthma exacerbations

not routinely indicated but are useful in excluding alternative diagnoses. Indications to consider imaging include first wheezing episodes, asymmetric lung findings, unexplained fevers, lack of response to treatment and critical illness. Likewise, routine arterial or capillary blood gases generally do not play much of a role unless the child is critically ill, where they can guide ICU interventions. Children with ‘normal range’ carbon dioxide levels, despite respiratory distress and tachypnoea, are at high risk for hypercapnic respiratory failure as this value is inappropriately high.

Based on clinical assessment, AAEs are classified by clinicians as either mild, moderate, severe or critical (also referred to as near-fatal or life-threatening AAE in some guidelines) (Table 3). There are minor variations in these AAE severity definitions across different guidelines but they are conceptually similar and all largely derived from US guidelines. Several validated clinical scoring tools have been developed to better aid the accuracy and precision of determining AAE severity. These scores include the modified Pulmonary Index Score (PIS), the Paediatric Asthma Severity Score (PASS), the

---

**Table 3. Classification of acute asthma exacerbation severity in children.**

| Symptoms | Mild | Moderate | Severe | Critical |
|----------|------|----------|--------|----------|
| **Breathlessness/speech** | Whilst walking | At rest | At rest (sits upright) | |
| **Talks in** | Sentences | Phrases | Words | |
| **Mental status** | Normal | May be agitated | Usually agitated | Drowsy or confused |
| **Signs** | Minimal intercostal retraction | Intercostal and substernal retraction | Significant distress; all accessory muscles involved; possible nasal flaring, paradoxical breathing | Marked respiratory distress OR exhaustion/decreasing effort |
| **Wheeze** | Moderate wheeze | Loud expiratory and inspiratory wheeze | Audible wheezing | Silent chest |
| **Oxygen saturations** | >94% | 91–94% | <90% | <90% |
| **Peak expiratory flow versus personal best** | >80% | 60–80% | Best <60% | Unable to perform |

---

**Figure 1. Pathophysiology of an acute asthma exacerbation.** At baseline, children with asthma are primed with increased inflammatory cell populations. In response to trigger exposure, these inflammatory cells, along with hyperactive structural bronchial cells, produced excess inflammatory mediators. These inflammatory mediators interact with smooth muscle and epithelial lung cells to result in early bronchospasm. Continued production of inflammatory mediators results in later-stage inflammation leading to increased mucus production and edema. Both early and late bronchospasms result in progressive bronchiolar obstruction leading to hypoxia and hypoventilation.
Childhood Asthma Score (CAS)\textsuperscript{10} and the Paediatric Respiratory Assessment Measure (PRAM).\textsuperscript{31,32} PRAM is the only score endorsed by the one Canadian guideline reviewed.\textsuperscript{1} The PRAM score accurately reflects severity of airway obstruction, response to treatment\textsuperscript{33,34} and predicts the need for hospitalization 3 hours after initial ED presentation.\textsuperscript{35} In a single-centre cohort study of children aged 5–17 years, PRAM was more sensitive to clinical changes than spirometry.\textsuperscript{14}

Of note, the classification of severe asthma exacerbation should be differentiated from severe asthma (referring to the degree of baseline disease control). The terms ‘severe asthma’, ‘poorly controlled’ and ‘persistent asthma’ have overlapping definitions and are used interchangeably or in combination (i.e. persistent–severe) by different guidelines. Differentiating between these baseline control terms is beyond the scope of this review.

\section*{Subgoal: consideration of alternative and additional diagnoses}

Especially for patients with previous AAEs, it is crucial to avoid anchoring bias and exclude alternative causes for wheeze/respiratory distress. Critical differential diagnoses include bronchiolitis, anaphylaxis, pertussis, vocal cord dysfunction, heart failure, foreign body aspiration, cystic fibrosis and lower airway mass effects.\textsuperscript{20} Of note, in children <1 year of age, bronchiolitis is the most common reason for wheeze. Bronchiolitis is classically refractory to asthma pharmacotherapy and current treatment guidelines recommend against routine asthma medication ‘trials’ in children with this suspected diagnosis.\textsuperscript{36,37} Conversely, preschool children (aged 1–5 years) are classically underdiagnosed with asthma as they are too young to perform a PFT. A new Canadian guideline details a pragmatic approach to diagnosing asthma in preschool children and advocates that they receive asthma medications.\textsuperscript{38}

Furthermore, clinicians should consider comorbid diagnoses requiring additional treatments alongside AAEs. In the correct circumstances, concurrent anaphylaxis should always be considered, with intramuscular epinephrine administered in suspected cases. In younger children, underlying lung pathology, such as bronchopulmonary dysplasia, cystic fibrosis and triggers from nonaccidental injury, should be managed concurrently with AAEs. In toddlers and school-aged children, attention should be paid to concurrent atypical pneumonia requiring antibiotic therapy. A prospective study of 119 children aged 2–15 years hospitalized for severe asthma revealed that up to 20% had mycoplasma pneumonia, particularly in children experiencing their first AAE (50%).\textsuperscript{39} Finally, in older adolescents, clinicians should concurrently manage potential coingestions (i.e. smoking, cannabinoids, opioids), withdrawals, vaping-related lung injuries and comorbid mental health concerns.

\section*{Prompt and effective medical intervention}

Upon diagnosing an AAE and determining its severity, therapy should be promptly initiated. Evidence recommends using clinical pathways to improve the quality of care in acute settings. Clinical pathways are knowledge translation tools providing evidence-based, stepwise guidance on management goals, appropriate medications, doses, plans for escalating care and predefined admissions criteria. In a systematic review of seven studies involving 2600 asthmatic children in ED or inpatient settings, clinical pathway use was associated with decreased hospital length of stay.\textsuperscript{40} Additional data from multiple, large single-centre studies also found decreased odds of admission, after implementation of a pathway and a decrease in costs of patients seen in the ED (but not for inpatients).\textsuperscript{41–43} Furthermore, a recently published multisite study of ED asthma pathway implementation (83 ED with 22,963 visits) found that it was associated with significantly decreased odds of admission, increased odds of early systemic corticosteroid administration and triage severity assessments.\textsuperscript{46}

Several institution-specific pathways have been utilized in the previous studies with similar outcomes, suggesting no one superior pathway exists. Multiple pathways for the management of paediatric asthma exacerbations have been published by large, (inter)national paediatric asthma working groups.\textsuperscript{6,7,11–16} The recommended interventions are mostly shared and focus on five subgoals: (1) treatment of hypoxemia (if needed); (2) early administration of corticosteroids; (3) administration of bronchodilators; (4) administration additional critical care medications (if needed); and (5) regular reassessment for treatment response.

\section*{Subgoal: treatment of hypoxemia (if needed)}

Children with resting hypoxemia and spontaneous respiration require urgent supplemental oxygen. There is no consensus oxygen threshold, with cut-offs ranging between 90% and 94%.\textsuperscript{7,11,15} Hypoxemia prior to bronchodilator treatment is a marker of AAE severity. Children with hypoxemia seen in an ambulatory clinic should be transferred to an ED setting with prehospital services involved. Baseline saturations of <92% have been correlated with AAE severity and prolonged frequent bronchodilator therapy.\textsuperscript{11,47} Hypoxemia after 1 hour of bronchodilator treatment is a risk factor for hospitalization.\textsuperscript{7,11}

For children with mild hypoxemia and severe AAE, heliox is a potential adjunct therapy.\textsuperscript{7,11,15} Heliox is a low-density premixed mixture of helium and oxygen (70:30% or 79:21%), allowing improved laminar flow and decreased resistance that theoretically improves oxygenation and ventilation in constricted airways with AAEs. The efficacy of heliox remains unclear, with five randomized control trials (RCT) finding improved PFT and clinical symptoms but no decreased admissions or lengths of hospitalization.\textsuperscript{48–52} Of note, heliox is contraindicated in children with higher oxygen requirements (>30%).

\section*{Subgoal: early administration of systemic corticosteroids}

Systemic corticosteroids are the foundation to ‘controlling’ AAEs. Steroids decrease airway inflammation by reducing the numbers and activation of inflammatory cells and suppressing the production of immune modulators.\textsuperscript{52}
Whereas bronchodilators are critical for acute ‘rescue’ and stabilization, they are ultimately temporizing measures until corticosteroids take effect after 4–8 hours. As such, early administration of oral steroids within 1 hour of presentation has been strongly associated with reduced hospitalization, the need for ED presentation and duration of symptoms.\textsuperscript{53–55}

This review deliberately places the administration of systemic corticosteroids in advance of bronchodilator therapy to emphasize early administration. The recommended steroids and dosages are listed Table 4.\textsuperscript{6,7,11,38}

For children with mild AAEs, oral corticosteroids are not routinely indicated but may be prescribed based on the child’s underlying control and previous history.\textsuperscript{7} Of note, for children aged 5–11 years with mild AAE managing at home, increasing inhaled corticosteroid doses (traditionally 4–5x baseline controller doses) is no longer recommended due to new evidence suggesting no effect.\textsuperscript{6,7,11–16}

For children with moderate/severe AAEs, oral systemic corticosteroids are strongly recommended.\textsuperscript{6,7,11–16} Historically, oral prednisolone (active metabolite)/prednisone (prodrug) are recommended with good evidence. A systematic review and meta-analysis of 12 RCTs (863 children and adults) found that early ED administration of prednisolone/prednisone significantly reduced admission rates.\textsuperscript{54} The duration of this course ranges from 3 to 5 days, with evidence showing equal benefit from both durations.\textsuperscript{57} Recently, guidelines have recommended the administration of oral dexamethasone as an alternative to oral prednisolone/prednisone.\textsuperscript{11,15}

Dexamethasone, a long-acting corticosteroid (half-life: 36–72 hours) that is six times more potent than prednisone (half-life: 18–36 hours), offers the theoretical advantage of single-dose administration and thereby greater adherence.\textsuperscript{58} A high-quality meta-analysis including data from 6 RCTs comparing children receiving 1–2 day courses of oral or intramuscular dexamethasone compared to 3–5 day courses of prednisolone or prednisone in children seen in ED with severe AAEs found no difference in relapse rates but significantly decreased vomiting in children receiving dexamethasone.\textsuperscript{59} Regardless of oral corticosteroid use, systematic review and meta-analysis suggest that they are generally safe with few acute systemic adverse drug events, including vomiting, hyperglycaemia and transient mood change. The impact of growth suppression from intermittent systemic corticosteroid doses remain uncertain from current studies.\textsuperscript{60,61}

In children with severe/critical AAEs, intravenous (i.v.) methylprednisolone (preferred for minimal mineralocorticoid effects) or i.v. hydrocortisone is recommended as oral medications may not be safely tolerated due to concerns of vomiting.\textsuperscript{15,52} However, there is no data suggesting that i.v. formulations provide additional efficacy benefits over oral formulations.\textsuperscript{52} Similarly, there is insufficient evidence to support increased intramuscular corticosteroids over oral formulations.\textsuperscript{62}

\textbf{Table 4. Recommended corticosteroids for acute asthma medications in children}\textsuperscript{,7,11,15,16}

| Name                        | AAE severity indication   | Route | Dosage$^a$                     | Frequency/course | Comments                                      |
|-----------------------------|---------------------------|-------|-------------------------------|------------------|-----------------------------------------------|
| Prednisone/prednisolone     | Moderate/severe (consider in mild) | Oral   | 1 mg/kg/dose (max 60 mg/dose) | Every 6 or 12 hours | Adrenal suppression may occur with repeat doses |
|                            |                           |        |                               |                  | i.v. administration possible but less preferred |
|                            |                           |        | 0.15–0.3 mg/kg/dose (max 10–16mg) |                  | Decreased vomiting compared to prednisone/prednisolone |
|                            |                           |        | 1–2 mg/kg/day (max 60 mg/day) | Every 6 or 12 hours | Less mineralocorticoid effects than hydrocortisone |
|                            |                           |        |                               |                  |                                               |
| Methylprednisolone          | Severe/critical           | i.v.   | 5–7 mg/kg/dose (max 400 mg/dose) | Every 6 hours    |                                               |

$^a$Disclaimer: Suggested doses are from North American and International Guidelines. Please refer and adhere to guidelines and recommendations to your local institution, pharmacist or regulatory board.

AAE, acute asthma exacerbation; i.v., intravenous.
and large airways, increasing intracellular cyclic adenosine monophosphate (cAMP).52 cAMP inhibits calcium release from intracellular stores, inhibiting smooth muscle contraction and reversing bronchoconstriction. Salbutamol (international nonproprietary name) or albuterol (US adopted name) is the general SABA of choice and is available in inhalational and i.v. formulations. Salbutamol is a 50:50 mixture of R-(active) and S-(inactive) enantiomers. Whilst levosalbutamol, a pure R-enantiomer theoretically offers more benefit, it is substantially more costly and limited RCT evidence does not support its superiority.63,64 In general, salbutamol is a safe medication, with adverse effects including transient tachycardia, tremors and hypokalaemia with repeated doses.61 Recommended dosages are listed in Table 5.

For children with mild/moderate AAEs, evidence strongly suggests salbutamol administered using metered-dose inhalers (MDIs) and spacer devices. A Cochrane systematic review and meta-analysis including 1897 children with mild/moderate AAEs in 39 trials found no significant difference (noninferior) in admission rates and PFT outcomes between children administered salbutamol compared to those administered MDIs and nebulizers.65 MDIs were associated with decreased lengths of stay, pulse rates and risks of tremor. A further incremental cost-effectiveness analysis of this Cochrane review revealed that MDIs were associated with major cost savings (~$155 Canadian per patient) to healthcare systems.66 Homemade spacer devices have similar efficacies compared to commercial versions.65

However, there is less evidence to support the use of MDIs with spacer devices in children with severe/critical AAEs as the previous studies excluded these patients. There is concern that children with severe/critical AAEs do not have adequate inspirational forces to sufficiently administer salbutamol via MDIs and spacers.52 As such, most guidelines recommend nebulized salbutamol for severe/critical AAEs.7,11-16 Evidence from adult studies suggests that continuous nebulization over 60–180 minutes results in significantly improved PFT at 2–3 hours and reduced admission rates compared to intermittent (1 nebulization every 15 minutes) nebulization.67

Adjunct bronchodilators Along with salbutamol, several adjunct bronchodilators play an important role in augmenting its effects in children with moderate-to-critical AAEs. The recommended doses of these adjunct bronchodilators are listed in Table 6.

Ipratropium bromide is a short-acting anticholinergic emerging in the early 2000s. Ipratropium bromide is indicated for moderate-to-critical AAEs showing no initial response to SABAs.7,11,13,15 It produces a mild bronchodilator effect by blocking the interaction of acetylcholine with muscarinic receptors on bronchial smooth muscle cells whilst also decreasing mucosal oedema and secretion.52 As it does not cross mucous membranes, the central anticholinergic side effects are minimal, with occasional mydriasis, dry mucous membranes and blurred vision reported.52 Several studies have been conducted, with strong evidence supporting reduced hospitalization rates in children with moderate-to-severe AAE. A systematic review of 2697 children (20 trials) aged 1–18 years with moderate/severe exacerbations found that adding nebulized ipratropium bromide to salbutamol in ED settings significantly reduced the odds of hospital admission.68 The addition of ipratropium bromide also significantly improved PFT and clinical scores at 120 minutes, oxygen saturation at 60 minutes and the need for repeat salbutamol use as well as decreasing nausea (but not vomiting) and tremor compared to salbutamol alone.68

Several limitations of ipratropium bromide should be noted. The majority of children studied were >2 years old. A systematic review and meta-analysis of 321 infants aged <2 years from six parallel control trials found a decreased need for additional treatment compared to salbutamol alone in an

---

**Table 5. Recommended primary bronchodilators for acute asthma exacerbations in children.**

| Name                  | AAE severity indication | Route          | Dosagea | Frequency/course | Comments                                           |
|-----------------------|-------------------------|----------------|---------|-----------------|----------------------------------------------------|
| Salbutamol (albuterol) | Home/mild/moderate      | MDI with spacer| (100 µg/puff) Home: 2–6 puffs Mild/moderate: 4 puffs (<20 kg) or 8 puffs (>20 kg) | Home: every 20 minutes (max: 2 sets) Mild/moderate: every 20 min for the first hour, then every 30–60 min as needed | Repeat doses optional for mild AAE — If available, continuous is preferred — Monitor potassium |
| Salbutamol (albuterol) | Severe/critical         | Nebulizer      | 2.5 mg (<20 kg) or 5 mg (>20 kg) | Every 20 minutes for the first hour OR continuous for 60–180 min, then every 30–60 min as needed | — If available, continuous is preferred — Monitor potassium |

*aDisclaimer: Suggested doses are from North American and International Guidelines. Please refer and adhere to guidelines and recommendations to your local institution, pharmacist or regulatory board. AAE, acute asthma exacerbation; MDI, metered dose inhaler.*
Table 6. Recommended adjunct bronchodilators for acute asthma exacerbations in children\textsuperscript{2,11,15,16}

| Name                  | AAE severity indication | Route          | Dosage\textsuperscript{a}                          | Frequency/course                  | Comments                                      |
|-----------------------|-------------------------|----------------|----------------------------------------------------|------------------------------------|-----------------------------------------------|
| Ipratropium bromide   | Moderate/severe         | MDI with spacer| (17 µg/puff) 3–4 puffs (<20 kg) 6–8 puffs (>20 kg) | Every 20 minutes for first hour    |                                               |
| Ipratropium bromide   | Severe/critical         | Nebulizer      | 250 µg (<20 kg) or 500 µg (>20 kg)                 | Every 20 minutes for first hour    | Can mix with salbutamol nebulization          |
| Magnesium sulfate     | Moderate/severe/critical| i.v.           | 25–50 mg/kg i.v. bolus over 20–30 min (maximum 2 g) | – Watch for hypotension            |                                               |

\textsuperscript{a}Disclaimer: Suggested doses are from North American and International Guidelines. Please refer and adhere to guidelines and recommendations to your local institution, pharmacist or regulatory board.

AAE, acute asthma exacerbation; MDI, metered dose inhaler.

ED setting but no changes in the length of stay in hospitalized children, symptom improvement in ED or in the number of hospitalized patients.\textsuperscript{69} Furthermore, the beneficial effects of ipratropium as an adjunct agent appear to decline with repeated doses. Numerous studies have found that ipratropium bromide with salbutamol in hospitalized children does not result in reduced lengths of stay or symptom improvements compared to salbutamol alone.\textsuperscript{70} As such, several guidelines for acute asthma exacerbation limit ipratropium bromide to the initial first hour of management only.\textsuperscript{71–13,15,16} Finally, several guidelines extrapolate the benefits of MDI and spacer with salbutamol with emerging evidence suggesting that ipratropium bromide delivered in this fashion does not reduce admission rates.\textsuperscript{7,11,15,71,72}

Magnesium sulfate (i.v.) also emerged in the early 2000s as a key adjunctive bronchodilator in children with severe-to-critical AAE not responding to repeated or continuous salbutamol and/or ipratropium bromide nebulization.\textsuperscript{7,11,15,16} Magnesium is a competitive antagonist for calcium receptors. In addition to inactivating inflammatory cells, magnesium causes bronchiolar smooth muscle relaxation by inhibiting the calcium uptake of myosin fibres required for smooth muscle contraction.\textsuperscript{52} Several meta-analyses, combining small numbers from heterogenous studies have shown significant decreases in rates of hospitalization of children with severe AAEs refractory to repeated/continuous nebulized SABAs (at high likelihood of admission) when administered i.v. magnesium sulfate compared to placebo.\textsuperscript{73–75} However, as the prevalence of children with severe AAEs is relatively low, there is less evidence for magnesium compared to other bronchodilators. There is limited evidence on the effects of i.v. magnesium on ICU admission rates or length of stay. Most studies utilized dosages from 25 to 50 mg/kg/dose, with occasional studies and ICU experts recommending doses of 75 mg/kg for children with critical AAEs to more rapidly achieve higher serum magnesium concentrations.\textsuperscript{52,73} Generally, i.v. magnesium sulfate is safe, with side effects including hypotension under rapid infusion, respiratory depression, facial warmth/flushing, muscle weakness, vision changes and dry mouth.\textsuperscript{76} Of note, recently, nebulized magnesium sulfate has been shown to be ineffective as an adjunct therapy in a randomized placebo-controlled, multi-centre parallel trial of 508 children.\textsuperscript{77}

Subgoal: administration of critical care medications/therapies (if needed)

On occasions where children with severe/critical AAEs are refractory to the previous medications, second-line bronchodilators and additional critical care medications as well as ventilation interventions are required. These children, classically termed to be in ‘status asthmaticus’, are at high risk of respiratory failure and require ICU management. Evidence supporting these interventions in children is sparse, owing, fortunately, to the rarity of critical AAEs. As a result, international guidelines do not take a position on these medications,\textsuperscript{7} whilst national guidelines diverge, resulting in more variability in care\textsuperscript{78} (Table 7).

Classically, the methylxanthine theophylline (an i.v. form of aminophylline) is recommended for the treatment of critical AAEs. Whilst their precise mechanism of action is unclear, methylxanthines are thought to primarily produce a bronchodilator effect by inhibiting phosphodiesterase enzymes that break down cAMP. This increase in cAMP, combined with a possible increase in respiratory drive, catecholamine release, prostaglandin antagonism and inhibition of afferent neuronal activity, is thought to improve pulmonary function.\textsuperscript{52} However, in recent years, methylxanthines have fallen out of favour due to concerns of adverse events outweighing the clinical benefit. A systematic review of 7 controlled trials and 380 children admitted with critical AAEs found that the addition of aminophylline to systemic steroids and nebulized SABAs improved PFTs but did not affect symptoms, length of stay, ICU admission and mechanical ventilation rates, whilst leading to a three-fold

\textsuperscript{7}Disclaimer: Suggested doses are from North American and International Guidelines. Please refer and adhere to guidelines and recommendations to your local institution, pharmacist or regulatory board.

AAE, acute asthma exacerbation; MDI, metered dose inhaler.
Table 7. Recommended secondary bronchodilators and critical care medicines for acute asthma exacerbations in children.7,11,15,16

| Name              | AAE severity indication | Route | Dosage* | Frequency/course | Guidelines endorsed by |
|-------------------|-------------------------|-------|---------|-----------------|------------------------|
| Aminophylline     | Critical                | i.v.  | 5 mg/kg loading dose (omit if on baseline oral theophylline) followed by 1 mg/kg/h infusion | Infusion monitored by ICU Narrow therapeutic index | CPS, ICON, BTS/SIGN, PRACTALL Not recommended by NHLBI, GINA |
| Salbutamol        | Critical                | i.v.  | 7.5 µg/kg bolus over 5 min OR 15 µg/kg bolus over 10 min, followed by 1–2 µg/kg/min infusion (max 5 µg/kg/min) | Infusion monitored by ICU | CPS, ICON, Australia, BTS/SIGN, PRACTALL, TREKK |
| Terbutaline       | Critical                | s.c./i.v. | s.c.: 0.01 mg/kg (max 0.25 mg/dose) i.v.: 2–10 µg/kg over 10 min, then 0.1–10 µg/kg/min infusion | s.c.: Every 20 min for first hour, then every 2–6 hours as needed | NHLBI (s.c. – transport setting only) |
| Epinephrine       | Critical                | i.m.  | 1 mg/mL (1:1000) 0.01 mg/kg (max 0.5 mg) | Every 20 min for first hour | NHLBI, GINA (if concerned anaphylaxis only) |
| Ketamine          | Critical                | i.v.  | Bolus 1–2 mg/kg, followed by 20–60 µg/kg/min infusion | | BTS/SIGN |

*Disclaimer: Suggested doses are from North American and International Guidelines. Please refer and adhere to guidelines and recommendations to your local institution, pharmacist or regulatory board.

AAE, acute asthma exacerbation; BTS/SIGN, British Thoracic Society/Scottish Intercollegiate Guidelines Network, CPS, the Canadian Paediatric Society; GINA, the Global Initiative for Asthma; ICON, International Consensus on Pediatric Asthma; i.m., intramuscular; i.v., intravenous; NHLBI, National Heart, Lung, and Blood Institute Expert Panel 3; PRACTALL, joint guidelines from the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology; s.c., subcutaneous; TREKK, Translating Emergency Knowledge for Kids.

In contrast, i.v. SABAs are increasingly recommended despite somewhat limited evidence. Currently, two i.v. SABAs are indicated, namely terbutaline and salbutamol. These two SABAs are pharmacologically similar, with terbutaline commonly used in the United States52 and salbutamol elsewhere. Evidence for i.v. SABAs is limited, with a 2012 systematic review identifying only two RCTs with 46 children in an ICU setting and 29 children in an ED setting. These studies report earlier reductions in the need for recurrent SABA and slight increases in PFTs but no reductions in lengths of ICU admission or length of hospitalization.81 However, a more recent retrospective chart review of 120 children found an association between early initiation of i.v. terbutaline and reduced respiratory failure, ICU admission, and mechanical ventilation.82 A systematic review comparing the efficacy of i.v. aminophylline and i.v. SABAs in children and adults of status asthmaticus revealed no significant difference in lengths of stay and pulmonary function but a markedly increased risk of adverse effects of giddiness, vomiting and nausea in children administered i.v. aminophylline.83 The adverse effects of i.v. SABAs include tachycardia, diastolic hypotension, hypokalaemia and cardiac ischaemia.82 Regarding the latter, multiple prospective case series in children on i.v. terbutaline infusions have found transient increases in troponins but no clinically significant cardiac injury.84–86

Injected β-agonists, subcutaneous terbutaline and intramuscular epinephrine are recommended exclusively by one US guideline as a secondary bronchodilator primarily in a prehospital setting or suspected comorbid anaphylaxis.11 Evidence supporting these medications is especially sparse, originating in the early 1980s from multiple small single-centre studies.87–89

Finally, ketamine, a dissociative anaesthetic, analgesic and sedative, is a known bronchodilator indicated for children in truly refractory status asthmaticus with impending respiratory failure/death requiring mechanical ventilation.52,90 Ketamine produces bronchodilator effects through various mechanisms, including N-methyl-D-aspartic acid receptor antagonism (which normally cause bronchial smooth muscle contraction), compensation for airway obstruction, and is associated with a number of side effects.
endogenous catecholamine release, anticholinergic effects and immunomodulation. The evidence to support ketamine in critical AAEs with children is mixed, with one placebo-controlled RCT in ventilated children in an ED setting demonstrating no differences in clinical status, admission, and mechanical ventilation and another observational study finding improved clinical status and PFT. In ventilated children in the paediatric ICU with bronchospasm and asthma, retrospective chart reviews have demonstrated improved PFT and compliance. The adverse effects of ketamine are minimal with occasional sialorrhoea and hallucinations.

**Mechanical ventilation** A detailed discussion on mechanical ventilation is beyond the scope of this review. Indications to consider mechanical ventilation include impending respiratory arrest, cardiopulmonary arrest, severe hypoxia refractory to second-line bronchodilators and rapid deterioration in a child’s mental state. Intubated children are at risk of air trapping and overinflation, requiring specific ventilatory strategies, including permissive hypercapnia (contraindicated if increased intracranial pressure, cardiac failure, toxic overdose), low peak inspiratory pressures, low tidal volumes and longer expiratory times. Critical care expertise is required.

**Subgoal: regular reassessment of treatment response** All medications and interventions require repeated assessment and adjustments based on patient status. AAE management pathways/protocols and clinical scoring tools such as PRAM are particularly helpful by inserting time posts for regular reassessments, suggested interventions and objective reassessment criteria. Important reassessment points include the reassessment of AAE severity at 1 and 2 hours postadministration of SABAs (usual endpoints for repeat salbutamol MDI or continuous nebulized salbutamol) and 3–4 hours after systemic corticosteroid administration (usual time of onset). Children showing improvements in AAE severity can have bronchodilator therapy gradually tapered under close supervision. Conversely, children with AAEs that do not improve or worsen require continued or escalated therapy.

**Appropriate patient disposition** Children with AAEs can present in the ambulatory clinic, urgent care or ED settings. In some cases, children will arrive after home management adhering to written asthma action plans. Regardless of location, assessing disposition for safe ongoing care is a continuous process.

For children managing at home or presenting to clinical settings, determination of the need to transfer to ED care is critical. The children meeting the following criteria should be immediately transferred for ED care: failure of SABA response (home action plans: symptoms are not relieved promptly with inhaled SABAs – >6 puffs of SABAs for symptom relief in the first 2 hours or no recovery after 24 hours; ambulatory settings: severe AAE failing to resolve within 1–2 hours despite three repeated doses of inhaled SABA); persistent tachypnoea (>40) despite repeated SABA treatment, even if the child shows other clinical signs of improvement; severe/critical AAE signs; lack of capacity for ongoing care; recurrence of signs of severe exacerbation within 48 hours of therapy (especially if systemic corticosteroids already administered); or the child has risk factors for fatal asthma.

For children in an ED, indications for hospitalization and ICU consultation can vary considerably. In general, children that should be admitted include those with ongoing need for supplemental oxygen; severe AAE despite 1–2 hours of continuous nebulization salbutamol (potential ICU admission); continued moderate AAE for more than 4–6 hours after corticosteroid administration; continued deterioration on conventional treatments; social environment limiting the delivery of care; and risk factors for fatal asthma with a child living at a major geographic distance from appropriate care.

In contrast, children can be considered for ED discharge if they have SABA use <4-hour intervals after 4–8 hours of treatment; adequate oxygen saturations on room air; minimal signs of respiratory distress; improved PFTs (if capable to perform); baseline ambulation and drinking; and safe ongoing monitoring at home.

**Appropriate discharge and follow-up instructions** Fortunately, the estimated mortality rate of children with AAEs is low, with a mortality rate of 2.6 per million in 2018 in the United States. Whilst this value does reflect asthma’s burden of illness, it highlights that the vast majority of children with appropriately managed AAE will be eventually discharged home. To reduce future AAEs, guidelines suggest that all children being discharged home from medical care should have the following: written and verbal instructions on signs of recurrence and worsening asthma; assessment of chronic asthma control (triggers for the AAE should be identified and risks mitigated); a written, individualized action plan, with details for ED care; review of MDI and spacer technique and medications; prescriptions and adequate supplies of SABAs and remaining courses of oral corticosteroids (if applicable); follow-up arranged with primary healthcare providers within 1–2 days of discharge and another in 1–2 months (evidence suggests that telephone follow-up may be a feasible option; social supports improve adherence with low-income families); and paediatric allergist or respirology referrals for critical AAEs.

**Discussion** Several advances in medications and strategies in managing paediatric AAEs have been highlighted. Intriguingly, despite the increasing global prevalence, rates of hospitalization in all asthmatic children in North America and high-income countries have declined from the 1980s to date, suggesting improved AAE care and underlying control.
In most guidelines, AAE management exists independent and in parallel to long-term disease control. Whereas control strategies focus on individualized care plans to manage the highly heterogeneous phenotypes of asthma, guidelines advocate for pathway/protocol-driven care, except in extreme circumstances of critical AAEs. These AAE pathways are guided by the severity of the AAE with treatment largely independent of baseline control. These treatment pathways revert more to expert opinion and individualistic approaches as available evidence diminishes with managing the rare child that presents with status asthmaticus.

In reality, the integral relationship between AAE and long-term asthma control is less distinct than currently conceptualized. On the one hand, the majority of AAEs are preventable and their occurrence reflects disease control. On the other, chronic control influences serial reoccurrences of AAEs and affect AAE severity and therapy responsiveness. It is critical that all caregivers consider both the acute and chronic implications of AAEs in children.

**Conclusion**

Ultimately, AAEs in children remain a significant burden on children’s health and substantial work is required to improve the care of children with AAEs. Identified directions for continued growth include higher quality studies on ideal dosing, duration, and efficacy of existing pharmacotherapies and mechanical ventilation (particularly with critical AAEs) targeting outcomes such as hospitalization rates and including data from diverse populations; increased understanding of adverse drug events and developmental impacts of AAE; novel pharmacotherapies; strategies to deliver equitable care for children from identified racial minority and disadvantaged socioeconomic backgrounds; improved knowledge translation and implementation of AAE pathways; and improved integration of AAEs and long-term asthma care approaches.

**Key practice points**

- Viral infections are the most common trigger for acute asthma exacerbations (AAEs) in children. Some children may need concurrent treatments for other disease processes (i.e. atypical pneumonia, anaphylaxis) that occur in addition to their AAE.
- AAEs in children are classified by severity as mild, moderate, severe or critical based on clinical criteria. Bedside pulmonary function testing is de-emphasized in children, as many cannot accurately or reliably perform the test. There is a limited role for routine lab-work and diagnostic imaging.
- The goals of care in managing children with AAEs are (1) immediate and objective assessment of AAE severity; (2) prompt and effective medical interventions; (3) appropriate disposition of patient; and (4) safe discharge home plans.
- Prompt and effective medical interventions for children with AAEs include (1) treatment of hypoxemia (if needed); (2) early administration of corticosteroids; (3) administration of bronchodilators with frequent reassessment; (4) administration of additional critical care medications (if needed); and (5) regular reassessment for treatment response.
- Strong evidence supports the early administration of oral corticosteroids and short-acting β-agonists as primary bronchodilators. Adhering to an asthma pathway based on the severity of the AAE improves the quality of care delivered.
- In contrast with long-term asthma control strategies that are individualized for each patient, AAEs are generally managed by generic stepwise pathways based on illness severity. However, critically ill children with AAEs frequently receive individualized management in the ICU as there is less evidence of efficacy for secondary bronchodilators in this group.
REVIEW – How to manage paediatric acute asthma exacerbations

References

1. Asher I, Pearce N. Global burden of asthma among children. *Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis*. 2014;18(11):1269–1278. https://doi.org/10.5588/ijtld.14.0170

2. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet*. 2006;368(9537):733–743. https://doi.org/10.1016/S0140-6736(06)69283-0

3. Croisant S. Epidemiology of asthma: prevalence and burden of disease. *Adv Exp Med Biol*. 2014;795:17–29. https://doi.org/10.1007/978-1-4614-8603-9_2

4. Ismaila AS, Sayani AP, Marin M, Su Z. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. *BMC Pulm Med*. 2013;13:70. https://doi.org/10.1186/1471-2466-13-70

5. Canadian Institute for Health Information. *Asthma Hospitalizations among Children and Youth in Canada: Trends and Inequalities*. Ottawa, ON: CIHI; 2018. https://www.cihi.ca/sites/default/files/document/asthma-hospitalization-children-2018-chartbook-en-web.pdf. Accessed November 20, 2020.

6. Papadopoulos NG, Arakawa H, Carlsen K-H, et al. International Consensus On (ICON) pediatric asthma. *Allergy*. 2012;67(8):976–997. https://doi.org/10.1111/j.1398-9995.2012.02865.x

7. Global Strategy for Asthma Management and Prevention (2020 Update). Global Initiative for Asthma; 2020. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-_final_-_wms.pdf. Accessed November 15, 2020.

8. Subbarao P, Mandhane PJ, Sears MR. Asthma: epidemiology, etiology and risk factors. *Can Med Assoc J*. 2009;181(9):E181-E190. https://doi.org/10.1503/cmaj.080612

9. CDC. Most Recent National Asthma Data. Published October 28, 2020. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. Accessed November 20, 2020.

10. Guttmann A, Zagorski B, Austin PC, et al. Effectiveness of emergency department asthma management strategies on return visits in children: a population-based study. *Pediatrics*. 2007;120(6):e1402–1410. https://doi.org/10.1542/peds.2007-0168

11. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. *Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma*. Bethesda, MD: National Heart, Lung, and Blood Institute (US); August 2007. https://www.ncbi.nlm.nih.gov/books/NBK7232/. Accessed November 19, 2020.

12. Bacharier LB, Boner A, Carlsen K-H, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. *Allergy*. 2008;63(1):5–34. https://doi.org/10.1111/j.1398-9995.2007.01586.x

13. National Asthma Council Australia. *Initial Management of Life-Threatening Acute Asthma in Adults and Children*. *Australian Asthma Handbook, Version 2.1*. National Asthma Council Australia; 2020. https://d30b7sro7pe7m.cloudfront.net/uploads/2020/08/figure_managing_acute_asthma_in_children_web.pdf. Accessed November 30, 2020.

14. BTS/SIGN. *British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN) Guideline for the Management of Asthma 2019*. https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/. Accessed December 6, 2020.

15. Ortiz-Alvarez O, Mikrogianakis A. Managing the paediatric patient with an acute asthma exacerbation. *Paediatr Child Health*. 2012;17(5):251–256. https://doi.org/10.1093/pch/175.251

16. TRanslating Emergency Knowledge for Kids (TREKK). Pediatric Severe Asthma Algorithm for children age > 12 months. Published March 1, 2020. https://trekk.ca/system/assets/assets/attachments/465/original/2020-03-18_Asthma_algorithm_v_1.2.pdf?1585618853. Accessed December 1, 2020.
REVIEW – How to manage paediatric acute asthma exacerbations

Leung JS. Drugs in Context 2021; 10: 2020-12-7. DOI: 10.7573/dic.2020-12-7
ISSN: 1740-4398

17. Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(1):5. https://doi.org/10.1186/s41073-019-0064-8

18. Saraya T, Kuriyama D, Ishii H, et al. Epidemiology of virus-induced asthma exacerbations: with special reference to the role of human rhinovirus. Front Microbiol. 2014;5:226. https://doi.org/10.3389/fmicb.2014.00226

19. Luz Garcia-Garcia M, Calvo Rey C, del Rosal Rabes T. Pediatric asthma and viral infection. Arch Bronconeumol. 2016;52(5):269–273. https://doi.org/10.1016/j.arbr.2016.03.010

20. Patel SJ, Teach SJ. Asthma. Pediatr Rev. 2019;40(11):549–567. https://doi.org/10.1542/pir.2018-0282

21. Lizzo JM, Cortes S. Pediatric Asthma. In: StatPearls. StatPearls Publishing; 2020. http://www.ncbi.nlm.nih.gov/books/NBK551631/. Accessed November 27, 2020.

22. Fixman ED, Stewart A, Martin JG. Basic mechanisms of development of airway structural changes in asthma. Eur Respir J. 2007;29(2):379–389. https://doi.org/10.1183/09031936.0005306

23. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368(9537):780–793. https://doi.org/10.1016/S0140-6736(06)69288-X

24. Malmstrom K, Pelkonen AS, Malmberg LP, et al. Lung function, airway remodelling and inflammation in symptom-free infants: outcome at 3 years. Thorax. 2011;66(2):157–162. https://doi.org/10.1136/thx.2010.139246

25. Gorelick MH, Stevens MW, Schultz T, Scribano PV. Difficulty in obtaining peak expiratory flow measurements in children with acute asthma. Pediatr Emerg Care. 2004;20(1):22–26. https://doi.org/10.1097/01.pec.0000016239.72265.16

26. Chacko J, King C, Harkness D, et al. Pediatric acute asthma scoring systems: a systematic review and survey of UK practice. J Am Coll Emerg Physicians Open. 2020;1(5):1000–1008. https://doi.org/10.1002/emp2.12083

27. Carroll CL, Sekaran AK, Lerer TJ, Schramm CM. A modified pulmonary index score with predictive value for pediatric asthma exacerbations. Ann Allergy Asthma Immunol. 2005;94(3):355–359. https://doi.org/10.1016/S1081-1206(10)60987-8

28. Koga T, Tokuyama K, Itano A, Morita E, Ueda Y, Katsunuma T. Usefulness of modified Pulmonary Index Score (mPIS) as a quantitative tool for the evaluation of severe acute exacerbation in asthmatic children. Allergol Int. 2015;64(2):139–144. https://doi.org/10.1016/j.alit.2014.10.003

29. Gorelick MH, Stevens MW, Schultz TR, Scribano PV. Performance of a novel clinical score, the Pediatric Asthma Severity Score (PASS), in the evaluation of acute asthma exacerbation. Acad Emerg Med. 2004;11(10):10–18. https://doi.org/10.1119/j.aem.2003.07.015

30. Parkin PC, Macarthur C, Saunders NR, Diamond SA, Winders PM. Development of a clinical asthma score for use in hospitalized children between 1 and 5 years of age. J Clin Epidemiol. 1996;49(8):821–825. https://doi.org/10.1016/0895-4356(96)00027-3

31. Ducharme FM, Chalut D, Plotnick L, et al. The pediatric respiratory assessment measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. J Pediatr. 2008;152(4):476–480, 480.e1. https://doi.org/10.1016/j.jped.2007.08.034

32. van der Windt D. Promises and pitfalls in the evaluation of pediatric asthma scores. J Pediatr. 2000;137(6):744–746. https://doi.org/10.1067/mpd.2000.111458

33. Chalut DS, Ducharme FM, Davis GM. The Preschool Respiratory Assessment Measure (PRAM): a responsive index of acute asthma severity. J Pediatr. 2000;137(6):762–768. https://doi.org/10.1067/mpd.2000.110121

34. Arnold DH, Gebretsadik T, Hartert TV. Spirometry and PRAM severity score changes during acute pediatric asthma exacerbation treatment in a pediatric emergency department. J Asthma. 2013;50(2):204–208. https://doi.org/10.3109/02770903.2012.752503

35. Alnaji F, Zemek R, Barrowman N, Plint A. PRAM score as predictor of pediatric asthma hospitalization. Acad Emerg Med Off J Soc Acad Emerg Med. 2014;21(8):872–878. https://doi.org/10.1111/acem.12422

36. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014;(6):CD001266. https://doi.org/10.1002/14651858.CD001266.pub4

37. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502. https://doi.org/10.1542/peds.2014-2742

38. Ducharme FM, Dell SD, Radhakrishnan D, et al. Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society position paper. Paediatr Child Health. 2015;20(7):353–371. https://doi.org/10.1093/pc/hvt028

39. Biscardi S, Lorrot M, Marc E, et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;38(10):1341–1346. https://doi.org/10.1086/392498

40. Chen K-H, Chen C (Cliff), Liu H-E, Tseng P-C, Glassiou PP. Effectiveness of paediatric asthma clinical pathways: a narrative systematic review. J Asthma. 2014;51(5):480–492. https://doi.org/10.3109/02770903.2014.887728

41. Bekmezian A, Fee C, Weber E. Clinical pathway improves pediatrics asthma management in the emergency department and reduces admissions. J Asthma. 2015;52(8):806–814. https://doi.org/10.3109/02770903.2015.1019086

42. Walls TA, Hughes NT, Mullan PC, Chamberlain JM, Brown K. Improving pediatric asthma outcomes in a community emergency department. Pediatrics. 2017;139(1). https://doi.org/10.1542/peds.2016-0088
43. Rutman L, Migita R, Spencer S, Kaplan R, Klein EJ. Standardized asthma admission criteria reduce length of stay in a pediatric emergency department. *Acad Emerg Med*. 2016;23(3):289–296. https://doi.org/10.1111/acem.12890

44. Rutman L, Atkins RC, Migita R, et al. Modification of an established pediatric asthma pathway improves evidence-based, efficient care. *Pediarics*. 2016;138(6). https://doi.org/10.1542/peds.2016-1248

45. Iqbal SF, Brown KM. Improving timeliness and reducing variability in asthma care through the use of clinical pathways. *Clin Pediatr Emrg Med*. 2018;19(1):52–54. https://doi.org/10.1016/j.cpehm.2018.02.008

46. Kaiser SV, Johnson MD, Walls TA, et al. Pathways to improve pediatric asthma care: a multisite, national study of emergency department asthma pathway implementation. *J Pediatr*. 2020;223:100–107.e2. https://doi.org/10.1016/j.jpeds.2020.02.080

47. Mehta SV, Parkin PC, Stephens D, Keogh KA, Schuh S. Oxygen saturation as a predictor of prolonged, frequent bronchodilator therapy in children with acute asthma. *J Pediatr*. 2004;145(5):641–645. https://doi.org/10.1016/j.jpeds.2004.06.072

48. Bigham MT, Jacobs BR, Monaco MA, et al. Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. *Pediatr Crit Care Med*. 2010;11(3):356–361. https://doi.org/10.1542/pccm.2010-2136

49. Kim IK, Phrampus E, Venkataraman S, et al. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. *Pediatrics*. 2005;116(5):1127–1133. https://doi.org/10.1542/peds.2004-2136

50. Kudukis TM, Manthous CA, Schmidt GA, Hall JB, Wylam ME. Inhaled helium-oxygen revisited: effect of inhaled helium-oxygen during the initial ED treatment of status asthmaticus in children. *J Pediatr*. 1997;130(2):217–224. https://doi.org/10.1016/s0022-3476(97)70346-9

51. Rivera ML, Kim TY, Stewart GM, Minasyan L, Brown L. Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial. *Am J Emerg Med*. 2006;24(1):38–42. https://doi.org/10.1016/j.ajem.2005.06.007

52. Nievas IF, Anand KJS. Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. *J Pediatr Pharmacol Ther*. 2013;18(2):88–104. https://doi.org/10.5863/1551-6776-18.2.88

53. Sarzynski LM, Turner T, Stukus DR, Allen E. Home supply of emergency oral steroids and reduction in asthma healthcare utilization. *Pediatr Pulmonol*. 2017;52(12):1546–1549. https://doi.org/10.1002/ppul.23892

54. Edmonds ML, Milan SJ, Camargo Jr CA, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. *Cochrane Database Syst Rev*. 2012;12(12):CD002308. https://doi.org/10.1002/14651858.CD002308.pub2

55. Rachelefsky G. Treating exacerbations of asthma in children: the role of systemic corticosteroids. *Pediatrics*. 2003;112(2):382–397. https://doi.org/10.1542/peds.112.2.382

56. Jackson DJ, Bacharier LB, Mauger DT, et al. Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations. *N Engl J Med*. 2018;378(10):891–901. https://doi.org/10.1056/NEJMoa1710988

57. Chang AB, Clark R, Sloots TP, et al. A 5- versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalised: a randomised controlled trial. *Med J Aust*. 2008;189(6):306–310. https://doi.org/10.5694/j.1326-5377.2008.tb02046.x

58. Shefrin AE, Goldman RD. Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients. *Can Fam Physician*. 2009;55(7):704–706.

59. Keeney GE, Gray MP, Morrison AK, et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. *Pediatrics*. 2014;133(3):493–499. https://doi.org/10.1542/peds.2013-2273

60. Fernandez RM, Wingert A, Vandermeer B, et al. Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis. *BMJ Open*. 2019;9(8):e028511. https://doi.org/10.1136/bmjopen-2018-028511

61. Leung JS, Johnson DW, Sperou AJ, et al. A systematic review of adverse drug events associated with administration of common asthma medications in children. *Pediatr Pulmonol*. 2017;52(12):1546–1549. https://doi.org/10.1002/ppul.23892

62. Qureshi F, Zartisky A, Welch C, Meadows T, Burke BL. Clinical efficacy of racemic albuterol versus levosalbuterol for the treatment of acute pediatric asthma. *Ann Emerg Med*. 2005;46(1):29–36. https://doi.org/10.1016/j.annemergmed.2005.02.001

63. Rahman A. Levosalbutamol versus salbutamol for treatment of acute exacerbation of asthma in Bangladesh children. *J Allergy Ther*. 2012;3:3. https://doi.org/10.4172/2155-6121.1000123

64. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. *Cochrane Database Syst Rev*. 2013(9):CD000052. https://doi.org/10.1002/14651858.CD000052.pub3

65. Doan Q, Shefrin A, Johnson D. Cost-effectiveness of metered-dose inhalers for asthma exacerbations in the pediatric emergency department. *Pediaedics*. 2011;127(5):e1105–1111. https://doi.org/10.1542/peds.2010-2963

66. Camargo CA, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. *Cochrane Database Syst Rev*. 2003(4):CD001115. https://doi.org/10.1002/14651858.CD001115
68. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta₂-agonists for initial treatment of acute asthma in children. *Cochrane Database Syst Rev.* 2013;(8):CD000060. https://doi.org/10.1002/14651858.CD000060.pub2

69. Everard M, Bara A, Kurian M, N’Diaye T, Ducharme F, Mayove V. Anticholinergic drugs for wheeze in children under the age of two years. *Cochrane Database Syst Rev.* 2005;2005(3):CD001279. https://doi.org/10.1002/14651858.CD001279.pub2

70. Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta₂-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. *Cochrane Database Syst Rev.* 2014;7:CD010283. https://doi.org/10.1002/14651858.CD010283.pub2

71. Wyatt EL, Bolland ML, Doyle SK, Geelhoed GC. Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: a single-blinded randomised controlled trial. *J Paediatr Child Health.* 2015;51(2):192–198. https://doi.org/10.1111/jpc.12692

72. Nomura O, Ihara T, Morikawa Y, et al. Metered-dose inhaler ipratropium bromide for children with acute asthma exacerbation: a prospective, non-randomized, observational study. *Pediatr Int.* 2020;62(3):319–323. https://doi.org/10.1111/ped.14146

73. Griffiths B, Kew KM. Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. *Cochrane Database Syst Rev.* 2016;4:CD011050. https://doi.org/10.1002/14651858.CD011050.pub2

74. Cheuk DKL, Chau TCH, Lee SL. A meta-analysis on intravenous magnesium sulphate for treating acute asthma. *Arch Dis Child.* 2005;90(1):74–77. https://doi.org/10.1136/adc.2004.050005

75. Shan Z, Rong Y, Yang W, et al. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. *Respir Med.* 2013;107(3):321–330. https://doi.org/10.1016/j.rmed.2012.12.001

76. Bichara MD, Goldman RD. Magnesium for treatment of asthma in children. *Ann Allergy Asthma Immunol.* 2000;85(4):287–290. https://doi.org/10.3109/02770908909073265

77. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta adrenoceptor agonists for initial treatment of acute asthma in children. *Arch Dis Child.* 2013;98(4):277–282. https://doi.org/10.1136/adc.2004.050005

78. Bratton SL, Newth CJL, Zuppa AF, et al. Critical care for pediatric asthma: wide care variability and challenges for study. *Pediatrics.* 2012;130(1):e219–e235. https://doi.org/10.1542/peds.2011-0554

79. Mitra AA, Bassler D, Watts K, Lasserson TJ, Ducharme FM. Intravenous aminophylline for acute severe asthma in children. *Cochrane Database Syst Rev.* 2015;2:CD001276. https://doi.org/10.1002/14651858.CD001276.pub2

80. Nair P, Milan SJ, Rowe BH. Addition of intravenous aminophylline to inhaled beta(2)-agonists versus short-acting beta(2)-agonists for initial treatment of acute asthma in children. *Cochrane Database Syst Rev.* 2012;12:CD001799. https://doi.org/10.1002/14651858.CD001799.pub2

81. Travers AH, Jones AP, Camargo CA, Rowe BH. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. *Cochrane Database Syst Rev.* 2012;12:CD010179. https://doi.org/10.1002/14651858.CD010179

82. Doymaz S, Schneider J, Sagy M. Early administration of terbutaline in severe pediatric asthma may reduce incidence of acute respiratory failure. *Ann Allergy Asthma Immunol.* 2014;112(3):207–210. https://doi.org/10.1016/j.anai.2014.01.003

83. Travers AH, Jones AP, Camargo CA, Milan SJ, Rowe BH. Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. *Cochrane Database Syst Rev.* 2012;12:CD010256. https://doi.org/10.1002/14651858.CD010256

84. Chiang VW, Burns JP, Rifai N, Lipshultz SE, Adams MJ, Weiner DL. Cardiac toxicity of intravenous terbutaline for the treatment of severe asthma in children: a prospective assessment. *J Pediatr.* 2000;137(1):73–77. https://doi.org/10.1016/S0022-3476(00)00657-0

85. Stephanopoulos DE, Monge R, Schell KH, Wyckoff P, Peterson BM. Continuous intravenous terbutaline for pediatric status asthmaticus. *Crit Care Med.* 1998;26(10):1744–1748. https://doi.org/10.1097/00003495-199810000-00033

86. Mitra AA, Bassler D, Watts K, Lasserson TJ, Ducharme FM. Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. *Cochrane Database Syst Rev.* 2005;2:CD001276. https://doi.org/10.1002/14651858.CD001276.pub2

87. Travers AH, Jones AP, Camargo CA, Milan SJ, Rowe BH. Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. *Cochrane Database Syst Rev.* 2012;12:CD010256. https://doi.org/10.1002/14651858.CD010256

88. Chiang VW, Burns JP, Rifai N, Lipshultz SE, Adams MJ, Weiner DL. Cardiac toxicity of intravenous terbutaline for the treatment of severe asthma in children: a prospective assessment. *J Pediatr.* 2000;137(1):73–77. https://doi.org/10.1016/S0022-3476(00)00657-0

89. Stephanopoulos DE, Monge R, Schell KH, Wyckoff P, Peterson BM. Continuous intravenous terbutaline for pediatric status asthmaticus. *Crit Care Med.* 1998;26(10):1744–1748. https://doi.org/10.1097/00003495-199810000-00033

90. intended. Magnesium for treatment of asthma in children. *Ann Allergy Asthma Immunol.* 2000;85(4):287–290. https://doi.org/10.3109/02770908909073265

91. Chauhan BF, Ducharme FM. Intravenous aminophylline for acute severe asthma in children. *Ann Emerg Med.* 1996;22(9):972–976. https://doi.org/10.1010/8BF02044126
94. Petrillo T, Petrillo TM, Fortenberry JD, Linzer JF, Simon HK. Emergency department use of ketamine in pediatric status asthmaticus. *J Asthma*. 2001;38(8):657–664. https://doi.org/10.1081/JAS-100107543

95. Bhogal S, Zemek R, Ducharme FM. Written action plans for asthma in children. *Cochrane Database Syst Rev*. 2006;3:CD005306. https://doi.org/10.1002/14651858.CD005306.pub2

96. Schatz M, Rachelefsky G, Krishnan JA. Follow-up after acute asthma episodes. *Proc Am Thorac Soc*. 2009;6(4):386–393. https://doi.org/10.1513/pats.P09ST6

97. Craig SS, Dalziel SR, Powell CV, Graudins A, Babl FE, Lunny C. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of cochrane reviews. *Cochrane Database Syst Rev*. 2020;8:CD012977. https://doi.org/10.1002/14651858.CD012977.pub2

98. Puranik S, Forno E, Bush A, Celedón JC. Predicting severe asthma exacerbations in children. *Am J Respir Crit Care Med*. 2017;195(7):854–859. https://doi.org/10.1164/rccm.201606-1213PP